US Bancorp DE Has $9.35 Million Stock Holdings in Zoetis Inc. $ZTS

Key Points

• US Bancorp DE reduced its stake in Zoetis by 15.0% in the fourth quarter, selling 13,142 shares and ending the period with 74,322 shares valued at $9.35 million.
• Zoetis beat quarterly estimates with $1.48 EPS (vs. $1.40 expected) and $2.39 billion in revenue, and set FY 2026 guidance of 7.000–7.100 EPS (sell‑side forecast ~7.01).
• The company announced a quarterly dividend of $0.53 (annualized $2.12, yield 1.9%), while analyst coverage is mixed with an average rating of Hold and a consensus price target of $151.75.

US Bancorp DE decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 15.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,322 shares of the company's stock after selling 13,142 shares during the quarter. US Bancorp DE's holdings in Zoetis were worth $9,351,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the fourth quarter worth $25,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the third quarter worth $31,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis during the fourth quarter worth $38,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Down 0.7%

Shares of NYSE ZTS opened at $114.22 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a 52 week low of $112.97 and a 52 week high of $172.23. The stock has a market capitalization of $48.05 billion, a P/E ratio of 18.97, a PEG ratio of 1.76 and a beta of 0.87. The stock's fifty day moving average is $119.93 and its 200 day moving average is $124.67.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. During the same quarter last year, the business earned $1.40 earnings per share. Zoetis's revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts forecast that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis's payout ratio is currently 35.22%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ZTS shares. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a report on Friday, February 13th. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Citigroup started coverage on Zoetis in a report on Wednesday, April 15th. They set a "buy" rating and a $145.00 target price for the company. UBS Group dropped their target price on Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a report on Tuesday, April 28th. Finally, BTIG Research reissued a "buy" rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.